Valneva's 15min chart shows KDJ Death Cross, Bearish Marubozu formation.
PorAinvest
jueves, 9 de octubre de 2025, 1:06 pm ET1 min de lectura
VALN--
The delay in the Phase 3 data release, which was initially expected in late 2025, has been pushed back to the first half of 2026. Additionally, Valneva has revised its financial guidance for 2025, lowering its revenue projections from €180-190 million to €165-180 million and reducing its R&D investments from €90-100 million to €80-90 million [1][2].
The company cited "ongoing uncertainty" due to the FDA's suspension of the IXCHIQ vaccine license, which has further dampened investor confidence. Despite the challenges, Valneva has secured a debt facility for up to $500 million with Pharmakon Advisors, LP, extending its debt repayment timeline from Q1 2026 to Q4 2030. The new financing also includes more favorable terms, such as a lower interest rate and improved structure with a bullet maturity after five years [2].
Technical analysis of Valneva's 15-minute chart indicates a bearish trend, with a KDJ Death Cross and Bearish Marubozu pattern observed on October 9th, 2022 at 13:00. This suggests that the momentum of the stock price is shifting towards a downward trend, with potential for further decline. Sellers currently dominate the market, and this bearish momentum is likely to persist .
Based on the technical analysis of Valneva's 15-minute chart, a KDJ Death Cross and Bearish Marubozu pattern was observed on October 9th, 2022 at 13:00. This suggests that the momentum of the stock price is shifting towards a downward trend, with potential for further decline. Sellers currently dominate the market, and this bearish momentum is likely to persist.
Valneva SE (NASDAQ: VALN) has seen a significant decline in its stock price following the delay in the release of Phase 3 data for its Lyme disease vaccine and the suspension of its IXCHIQ vaccine by the FDA. The company's shares fell by 7% on the day of the announcement, with analysts attributing the drop to the uncertainty surrounding the vaccine's future [1].The delay in the Phase 3 data release, which was initially expected in late 2025, has been pushed back to the first half of 2026. Additionally, Valneva has revised its financial guidance for 2025, lowering its revenue projections from €180-190 million to €165-180 million and reducing its R&D investments from €90-100 million to €80-90 million [1][2].
The company cited "ongoing uncertainty" due to the FDA's suspension of the IXCHIQ vaccine license, which has further dampened investor confidence. Despite the challenges, Valneva has secured a debt facility for up to $500 million with Pharmakon Advisors, LP, extending its debt repayment timeline from Q1 2026 to Q4 2030. The new financing also includes more favorable terms, such as a lower interest rate and improved structure with a bullet maturity after five years [2].
Technical analysis of Valneva's 15-minute chart indicates a bearish trend, with a KDJ Death Cross and Bearish Marubozu pattern observed on October 9th, 2022 at 13:00. This suggests that the momentum of the stock price is shifting towards a downward trend, with potential for further decline. Sellers currently dominate the market, and this bearish momentum is likely to persist .
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios